Abstract

Allergy is an inflammatory process determined by a cascade of immune events characterized by T-helper 2 lymphocytes polarization leading to interleukin-4 upregulation, IgE secretion, and mast cell and eosinophil activation. HLA-G molecules, both in membrane-bound and in soluble forms, are known to play a key immunoregulatory role and their involvement in allergic diseases is supported by increasing literature data. HLA-G expression and secretion is specifically induced in peripheral blood mononuclear cells of allergic patients after in vitro incubation with the causal allergen. Elevated levels of soluble HLA-G molecules are detected in serum of patients with allergic rhinitis correlating with allergen-specific IgE levels, clinical severity, drug consumption and response to allergen-specific immunotherapy. HLA-G genetic polymorphisms confer susceptibility to allergic asthma development and high levels of soluble HLA-G molecules are found in plasma and bronchoalveolar lavage fluid of patients with allergic asthma correlating with allergen-specific IgE levels. Interestingly, allergic pregnant women have lower plasma sHLA-G levels than non-allergic women during the 3rd trimester of pregnancy and at delivery. Finally, in allergic patients with atopic dermatitis HLA-G molecules are expressed by T cells, monocytes-macrophages and Langerhans cells infiltrating the dermis. Although at present is difficult to completely define the role of HLA-G molecules in allergic diseases, it may be suggested that they are specifically expressed and secreted by immune cells during the allergic reaction in an attempt to suppress allergic inflammation.

Highlights

  • HLA-GHuman leukocyte antigen-G (HLA-G)Human leukocyte antigen-G (HLA-G) is an HLA class Ib antigen characterized by a restricted tissue expression, low polymorphism and 7 isoforms (HLA-G1 to HLA-G7) generated by alternative splicing of the primary HLA-G transcript [1, 2]

  • HLA-G may induce immune tolerance leading to the development of tolerogenic dendritic cells (DC) with induction of anergic and immunosuppressive T cells promoting the expansion of CD4+ CD25+ Forkhead Box P3 (FoxP3)+ T regulatory lymphocytes (Tregs) and triggering the differentiation of CD4+ T-cells in suppressor cells [9]

  • HLA-G seems to be involved in the tuning of immune responses, as incubation of peripheral blood mononuclear cells (PBMC) with HLA-G-expressing cells favors a shift towards a Th-2 cytokine profile, whereas incubation with soluble HLA-G molecules may have a counterbalancing effect by creating an anti-inflammatory environment due to the release of interleukin (IL)-10 [10, 11]

Read more

Summary

INTRODUCTION

Human leukocyte antigen-G (HLA-G) is an HLA class Ib antigen characterized by a restricted tissue expression, low polymorphism and 7 isoforms (HLA-G1 to HLA-G7) generated by alternative splicing of the primary HLA-G transcript [1, 2]. Increased percentages of circulating and tissue-infiltrating HLA-G+ immune cells (e.g., T and NK cells, monocytes, DCs, mast cells) can be observed in different pathological situations such as infections, cancers, transplants and autoimmune disorders suggesting a potential role for these cells in the pathogenesis of diseases in which immune system is strictly implicated [1, 2, 24, 36,37,38] Based on these findings, it has been proposed that HLA-G should be qualified as an ‘immune checkpoint’ molecule [39]. Serum sHLA-G levels are higher in patients with seasonal allergy than in those with perennial allergy [42,43,44,45,46, 51] sHLA-G levels significantly decrease 3 months after the end of allergen-specific immunotherapy and correlate with the increased production of IFN-g by peripheral blood mononuclear cells suggesting a successful shift from Th2 to Th1 immune response [52, 53]

Allergic rhinitis
IN VITRO DATA
CONCLUSIONS
Findings
Increased metastasis and worse outcome

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.